性行为感染传染病诊断市场－全球产业规模、份额、趋势、机会及预测（依产品、应用、技术、检测地点、地区及竞争格局划分，2021-2031年）

全球性行为感染传染病（STD）诊断市场预计将从 2025 年的 1,030.7 亿美元成长到 2031 年的 1,513.3 亿美元，复合年增长率为 6.61%。

此细分市场包括专门用于识别引起梅毒、淋病、披衣菌感染等感染疾病的病原体的试剂、仪器和耗材。市场成长的主要驱动力是这些感染疾病在全球日益普遍，以及政府为促进定期筛检以支持早期疗育和有效治疗而推出的各项措施。

根据美国性健康协会引用的2025年监测数据，报告的性行为感染总数比十年前的水平高出13%。虽然这种高发病率推动了市场需求，但围绕检测的社会污名却构成了市场发展的一大障碍。这种污名往往阻碍人们获得必要的诊断服务，从而抑制了市场渗透和普及。

市场驱动因素

全球性行为感染传染病（STD）发生率的不断上升是市场成长的根本驱动力，因此，健全的检测基础设施对于控制感染传播和预防长期併发症至关重要。细菌性行为感染的捲土重来，尤其是在已开发地区，迫使医疗系统采购大量基于分子和免疫检测分析的诊断耗材，以应对不断增长的患者群体。例如，根据英国卫生安全局2025年6月发布的报告，2024年英格兰早期梅毒诊断病例数将达到9535例，比前一年增长2%。同时，美国疾病管制与预防中心（CDC）2025年的初步数据显示，在2024年的监测期内，美国披衣菌感染、淋病和梅毒病例总合超过220万例，证实了诊断需求的持续成长。

同时，消费者对家用和自采检测套组的日益普及正在改变诊断格局，其方式是分散医疗服务，并绕过临床污名和预约等障碍。这项转变得益于监管机构核准了可在非医疗机构环境中提供检查室级准确度的商业化分子诊断平台。根据美国食品药物管理局 (FDA) 2025 年 3 月报告，Visby Medical 公司新核准的女性性健康检测套组在检验中对沙眼披衣菌的检测准确率达到了 97.2%。高性能自检测套组的广泛使用鼓励了年轻族群定期筛检，这不仅增加了直接面向消费者的製造商的收入，也减轻了性健康诊所的营运负担。

市场挑战

围绕性行为感染传染病的社会污名是全球诊断市场的主要限制因素，因为它阻碍了人们及时接受筛检。这种源自于害怕被评断、尴尬和隐私顾虑的心理障碍，使人们极不愿前往诊所或使用检测服务。因此，相当一部分高风险族群避免了必要的检测，这直接减少了临床环境中诊断试剂、试剂和耗材的消耗，限制了潜在市场规模，并阻碍了製造商的产生收入。

检测能力不足的后果体现在感染人数估计值与实际诊断率之间的差异。世界卫生组织（世卫组织）预测，到2024年，全球每天新增性行为感染将超过100万例，但仍有大量病例未被诊断。这些数据表明，儘管检测平台已经存在，但由于社会担忧有效地阻碍了患者进入诊断流程，市场无法充分利用不断上升的感染率。

市场趋势

多重核酸增幅检查(NAAT) 的出现，从根本上改变了临床工作流程，因为它能够同时检测单一患者检体中的多种病原体。这种向综合征检测的转变，解决了披衣菌感染和淋病等常见合併感染的问题，而这些感染往往会被单靶点检测漏诊。将检测整合到批次中，使检查室能够在确保全面诊断的同时，加快结果出具速度并降低营运成本，从而促进了其商业性应用。例如，Hologic 公司报告称，其分子诊断业务在 2024 年 11 月的收入增长了 9.4%，这主要得益于细菌性阴道炎、念珠菌性阴道炎和滴虫性阴道炎多重检测套组销量的增长。

同时，为性行为感染病原体日益严重的抗菌素抗药性威胁，次世代定序在基因组监测领域的应用正在加速。与传统诊断方法不同，基因测序能够帮助公共卫生机构识别特定的抗药性突变并追踪传播丛集，尤其是在淋病奈瑟菌。这项能力对于优化治疗通讯协定至关重要；正如世界卫生组织（世卫组织）2025年11月的一份报告指出，2022年至2024年间，头孢曲松和头孢克肟的抗药性预计将分别上升至5%和11%，因此亟需应对这些抗药性菌株。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球性行为感染传染病（STD）诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（设备/服务、耗材、软体）
  • 依用途（HIV 检测、HSV 检测、CT/NG 检测、梅毒检测、淋病检测、其他）
  • 依技术分类（免疫检测、分子诊断、其他）
  • 依检测地点（检查室检测、就地检验、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美性行为感染传染病（STD）诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲性行为感染传染病（STD）诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区性行为感染传染病（STD）诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲性行为感染传染病（STD）诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美性行为感染传染病（STD）诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球性行为感染传染病（STD）诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• bioMerieux SA
• Abbott Laboratories Inc.
• Danaher Corporation
• Qiagen NV
• Thermo Fisher Scientific Inc.
• DiaSorin SpA
• Bio-Rad Laboratories, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Sexually Transmitted Diseases (STD) Diagnostics Market is projected to expand from USD 103.07 Billion in 2025 to USD 151.33 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.61%. This sector comprises reagents, instruments, and consumables specifically designed to identify pathogens causing infections such as Syphilis, Gonorrhea, and Chlamydia. The market's growth is primarily driven by the rising global prevalence of these infections and the rollout of government initiatives that encourage routine screening to support early intervention and effective treatment.

According to 2025 surveillance data referenced by the American Sexual Health Association, the total number of reported sexually transmitted infections remained 13% higher than levels recorded ten years prior. While this elevated burden fuels demand, the market faces a significant obstacle due to the social stigma surrounding testing. This stigma often discourages individuals from accessing necessary diagnostic services, thereby impeding broader market penetration and adoption.

Market Driver

The escalating global incidence of sexually transmitted infections acts as a fundamental catalyst for market growth, necessitating a robust testing infrastructure to control outbreaks and prevent long-term complications. The resurgence of bacterial infections, especially in developed regions, compels healthcare systems to acquire increased volumes of molecular and immunoassay-based diagnostic consumables to manage the growing patient load. For instance, the UK Health Security Agency's June 2025 report noted that early-stage syphilis diagnoses in England reached 9,535 cases in 2024, a 2% annual increase, while provisional CDC data from 2025 indicated over 2.2 million total cases of chlamydia, gonorrhea, and syphilis in the United States for the 2024 surveillance period, reinforcing the sustained high demand for diagnostics.

Simultaneously, increasing consumer adoption of at-home and self-collection testing kits is reshaping the diagnostic landscape by decentralizing care and bypassing barriers such as clinical stigma and scheduling logistics. This shift is enabled by regulatory approvals of over-the-counter molecular platforms that provide lab-quality accuracy in private settings. As reported by the FDA in March 2025, the newly authorized Visby Medical Women's Sexual Health Test demonstrated 97.2% accuracy for Chlamydia trachomatis during validation. The availability of high-performance self-tests encourages frequent screening among younger demographics, driving revenue for direct-to-consumer manufacturers and alleviating operational pressure on sexual health clinics.

Market Challenge

Social stigma regarding sexually transmitted diseases constitutes a major restraint on the global diagnostics market by discouraging individuals from seeking timely screening. This psychological barrier, rooted in fear of judgment, embarrassment, or privacy concerns, creates a strong reluctance to visit clinics or utilize testing services. Consequently, a substantial portion of the at-risk population avoids necessary testing, which directly reduces the consumption of diagnostic tests, reagents, and consumables in clinical settings, thereby limiting the addressable market size and restricting revenue generation for manufacturers.

The consequence of this testing gap is highlighted by the disparity between infection estimates and actual diagnostic uptake. According to the World Health Organization, in 2024, more than 1 million sexually transmitted infections were acquired daily worldwide, yet a vast number of these cases remained undiagnosed. This data indicates that despite the availability of testing platforms, the market cannot fully capitalize on the rising prevalence of infections because social apprehension effectively blocks patient entry into the diagnostic ecosystem.

Market Trends

The transition toward Multiplex Nucleic Acid Amplification Tests (NAATs) is fundamentally changing clinical workflows by enabling the simultaneous detection of multiple pathogens from a single patient specimen. This shift toward syndromic panel testing addresses high rates of co-infections, such as chlamydia presenting with gonorrhea, which single-target assays often miss. By consolidating testing into one run, laboratories can reduce turnaround times and operational costs while ensuring comprehensive diagnosis, driving commercial adoption. For example, Hologic, Inc. reported a 9.4% increase in molecular diagnostics revenue in November 2024, largely driven by elevated sales of their multiplex assay for bacterial vaginosis, Candida vaginitis, and Trichomonas vaginalis.

Concurrently, the implementation of Next-Generation Sequencing for genomic surveillance is gaining momentum to combat the escalating threat of antimicrobial resistance in sexually transmitted pathogens. Unlike traditional diagnostics, genomic sequencing allows public health entities to identify specific resistance mutations and track transmission clusters, particularly for Neisseria gonorrhoeae. This capability is essential for tailoring treatment protocols, as highlighted by a November 2025 World Health Organization release which noted that resistance to ceftriaxone and cefixime rose to 5% and 11% respectively between 2022 and 2024, necessitating advanced genomic profiling to manage these resistant strains.

Key Market Players

• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• bioMerieux S.A.
• Abbott Laboratories Inc.
• Danaher Corporation
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• DiaSorin S.p.A
• Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sexually Transmitted Diseases (STD) Diagnostics Market, By Product

• Instruments And Services
• Consumables
• Software

Sexually Transmitted Diseases (STD) Diagnostics Market, By Application

• HIV Testing
• HSV Testing
• CT/NG Testing
• Syphilis Testing
• Gonorrhea Testing
• Others

Sexually Transmitted Diseases (STD) Diagnostics Market, By Technology

• Immunoassay
• Molecular Diagnostics
• Other

Sexually Transmitted Diseases (STD) Diagnostics Market, By Location Of Testing

• Laboratory Testing
• Point Of Care Testing
• Others

Sexually Transmitted Diseases (STD) Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sexually Transmitted Diseases (STD) Diagnostics Market.

Available Customizations:

Global Sexually Transmitted Diseases (STD) Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments And Services, Consumables, Software)
  • 5.2.2. By Application (HIV Testing, HSV Testing, CT/NG Testing, Syphilis Testing, Gonorrhea Testing, Others)
  • 5.2.3. By Technology (Immunoassay, Molecular Diagnostics, Other)
  • 5.2.4. By Location Of Testing (Laboratory Testing, Point Of Care Testing, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By Location Of Testing
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By Location Of Testing
  • 6.3.2. Canada Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By Location Of Testing
  • 6.3.3. Mexico Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By Location Of Testing

7. Europe Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By Location Of Testing
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By Location Of Testing
  • 7.3.2. France Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By Location Of Testing
  • 7.3.3. United Kingdom Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By Location Of Testing
  • 7.3.4. Italy Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By Location Of Testing
  • 7.3.5. Spain Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By Location Of Testing

8. Asia Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By Location Of Testing
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By Location Of Testing
  • 8.3.2. India Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By Location Of Testing
  • 8.3.3. Japan Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By Location Of Testing
  • 8.3.4. South Korea Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By Location Of Testing
  • 8.3.5. Australia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By Location Of Testing

9. Middle East & Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By Location Of Testing
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By Location Of Testing
  • 9.3.2. UAE Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By Location Of Testing
  • 9.3.3. South Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By Location Of Testing

10. South America Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technology
  • 10.2.4. By Location Of Testing
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By Location Of Testing
  • 10.3.2. Colombia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By Location Of Testing
  • 10.3.3. Argentina Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By Location Of Testing

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Sexually Transmitted Diseases (STD) Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Becton Dickinson and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Hologic, Inc.
• 15.4. bioMerieux S.A.
• 15.5. Abbott Laboratories Inc.
• 15.6. Danaher Corporation
• 15.7. Qiagen N.V.
• 15.8. Thermo Fisher Scientific Inc.
• 15.9. DiaSorin S.p.A
• 15.10. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer